About Drugs in Context

Drugs in Context is an open access, peer-reviewed, continuous publication of international standing. It is a member of the Directory of Open Access Journals (https://doaj.org/). It is listed on PubMed and all articles are free-to-view/download immediately on PubMed Central.

Latest rankings (SJR/Scimago 2019): equivalent Impact Factor = 3.56. Q2 title; H index = 15; SJR = 0.848. Ranked 15 of 80 open access pharmacology journals worldwide (based on eIF). Ranked 71 of 326 of all pharmacology journals worldwide (based on eIF).

Articles: we publish high-quality, peer-reviewed original research papers and topical review articles covering the latest evidence and innovations in drug treatment across all therapeutic areas. Other article types are considered.

Peer review: we conduct single-blind external peer review on all manuscripts with comments from at least two peer reviewers. Our aim is to obtain a first editorial decision within 3 weeks of manuscript submission and online publication within 3 weeks of acceptance.

Submit your manuscript: check the 'SUBMISSION' page for full instructions. Submit your manuscript via Manuscript Manager.

Latest Article

Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol

Teodoro Iturbe-Hernandez MD, Luis García de Guadiana Romualdo MD, Ignacio Gil Ortega MD, Antonio Martínez Francés MD, Olga Meca Birlanga MD, Juan José Cerezo-Manchado MD

Articles 2020

Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin

Lale Tokgözoglu MD, José Luis Zamorano MD

Neurological features of COVID-19 and their treatment: a review

Daniele Orsucci MD, Elena Caldarazzo Ienco MD, Gianpaolo Nocita MD, Alessandro Napolitano MD, Marco Vista MD

Nail enthesis ultrasound and automated software-guided assessment of bilateral common carotid intima–media thickness in psoriasis and psoriatic arthritis: is there a correlation with clinical and laboratory findings?

José Alexandre Mendonça PhD, Lucas Nogueira Pansani MD, Mateus Basso Mimoto MD, Igor Tadeu Garcia Ferreira MD, Fernanda Bertucci Sanches MD, Thais de Campos Ferreira Pinto MD, Vania Aparecida Leandro-Merhi PhD, José Luis Braga de Aquino PhD

Temozolomide and oral etoposide in children with recurrent malignant brain tumors

Antonio Ruggiero MD, Anna Ariano MD, Silvia Triarico MD, Michele Antonio Capozza MD, Alberto Romano MD, Palma Maurizi MD, Stefano Mastrangelo MD, Giorgio Attinà MD

A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic

Matteo Bassetti MD, PhD, Paolo Pelosi MD, FERS, Chiara Robba MD, PhD, Antonio Vena MD, PhD, Daniele Roberto Giacobbe MD